How effective is dendritic cell therapy in improving overall survival and progression-free survival in patients with advanced or recurrent non-small cell lung cancer, particularly when used in combination with standard treatments such as immune checkpoint inhibitors or chemotherapy?

DC vaccines appear to be safe and may improve outcomes in some patients with advanced/relapsed NSCLC, particularly when combined with chemotherapy or checkpoint inhibitors in early trials, but results from various studies and meta-analyses are mixed. Check more about Dendritic Cell Therapy for non small cell lung cancer! The transition to routine practice has not occurred due to the limited availability of high-quality randomized data—more rigorous combination trials (and agreed-upon endpoints for OS/PFS) are needed before this can be called a breakthrough.